Nasal Mucosa Drug Supply Device Market size was valued at USD 77.71 billion in 2022 and is projected to grow from USD 84.09 billion in 2023 to USD 178.47 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.4% during the forecast period (2023 - 2032). The rising adoption of small inhalers, rising prevalence of asthma and COPD drugs is driving the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The increasing prevalence of chronic respiratory disease has increased as compared to past years. The main causes of the increasing the burden of respiratory disease are increasing pollution, climate change, and a decline in immunity due to the sedentary lifestyle. Chronic respiratory disorder including interstitial pulmonary disease, asthma, pneumoconiosis, COPD, and other respiratory disease. These disorders are majorly impact on governments and society. As per the Australian Bureau of Statistics in 2021, around 2.7 million population suffered from asthma in Australia. In developing countries, respiratory illnesses make up over 80% of all illnesses. COPD impacted 200 million people worldwide in 2022.Compared to significant lifestyle conditions including hypercholesterolemia, hypertension, and others, COPD has a higher incidence rate. The number of patients suffering with chronic respiratory illnesses has increased by about 40% during the last 20 years. Thus, rising prevalence of asthma drive the growth of nasal drug delivery market across the globe.
The Nasal Mucosa Drug Supply Device Market segmentation, based on type, includes dry powder inhaler, metered dose inhaler, nebulizer. The dry powder inhaler segment is to hold the majority share in 2022 in the Nasal Mucosa Drug Supply Device Market revenue due to the dry powdered inhaler (DPI) is an asthma widely treatment solution for older kids and teens. Utilizing a dry powdered inhaler apportions medicine to get immersed into the lungs. Contrasting other inhalers which deliver a puff of medicine, these inhalers wedge the medicine as a dry powder.
July 2019: Eli Lilly and Company received FDA approval for its BAQSIMI (glucagon) nasal powder of 3 mg to treat severe hypoglycemia in patients with diabetes ages four years and above. Eli Lilly and Company announced that BAQSIMI is the first and only nasally administered glucagon, developed for severe hypoglycemia patients.
The Nasal Mucosa Drug Supply Device Market segmentation is based on applications that include asthma, chronic obstructive pulmonary disease, and others. The asthma segment has dominated the market in 2022 due to the increasing prevalence of asthma across the globe. Shorter treatment time is expected to drive the market growth. Moreover, this route of administration is the least expensive, convenient, and safe, which increases its popularity, hence driving the market growth. Oral route of administration is preferred mostly in the case of acute asthma. It is also preferably used for the treatment of asthma and COPD in children because it is difficult for them to use inhalers.
January 2023: Aptar Pharma, launched new product “APF Futurity “, its first multidose nasal spray pump developed to part of AptarGroup launched APF Futurity, its first metal-free, multidose nasal spray pump developed to distribute nasal saline in over-the-counter formulations.Â
The Nasal Mucosa Drug Supply Device Market segmentation is based on the distribution channel that includes hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment has dominated the market in 2022 due to the availability of proficient retailers and increasing demand for nasal drug inhalers retailers are keenly interested in investment in the nasal mucosa drug supply device market.
March 2019: Aptar Pharma received US FDA approval for its Bidose nasal spray device as a breakthrough therapy in the treatment of depression. This observes the first FDA approval and the US launch of a prescription drug using Aptar Pharma’s patented Bidose nasal spray delivery system.
Figure 2: NASAL MUCOSA DRUG SUPPLY DEVICE MARKET, BY DISTRIBUTION CHANNEL, 2022 & 2032 (USD BILLION)
 
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America accounted for the largest market share in 2022 owing to the North Americas is expected to command the largest market share due to the rising incidence of respiratory disease, increasing demand of nasal mucosa drug delivery system, business headquarter of major key players. For instance: Pfizer, Inc (US), OptiNose, Inc (US), Becton, Dickinson, and Company (US), Promius Pharma, LLC (US), and many other major key players having their business presence in the North America region which is driving the growth of nasal mucosa drug supply device market in the North America region. Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: NASAL MUCOSA DRUG SUPPLY DEVICE MARKET, BY REGION, 2022 & 2032 (USD BILLION)
NASAL MUCOSA DRUG SUPPLY DEVICE MARKET, BY REGION, 2022 & 2032
Europe Nasal Mucosa Drug Supply Device market is expected to account for the second-largest market share due to the growth of the market are increasing technological development and product innovation, rising research and development activity, highly investment by the major players for expanding their business in the region as well as government initiatives for the reducing risk of asthma across the region propel the growth of nasal drug supply delivery device market in the Europe. Furthermore, the Germany Nasal Mucosa Drug Supply Device market held the largest market share in 2022 and UK Nasal Mucosa Drug Supply Device market is the fastest growing market in the Europe region.
The Asia-Pacific nasal mucosa drug supply device market is expected to grow at a CAGR of 7.30% from 2019 to 2032. This is due to increasing healthcare expenditure, rising geriatric population, increasing strategic alliance such as expansion, merger, acquisition, supply, and distribution agreement. Moreover, Japan nasal mucosa drug supply device market held the largest market share in 2022 and India Nasal Mucosa Drug Supply Device market is the fastest growing market in the Asia-Pacific region.
The Rest of the World includes the Middle East, Africa, and Latin America. Latin America holds the major market share in the middle east and Africa region due to the region’s growth is attributed to an increasing awareness about the nasal drug delivery devices, rising medical facility, availability of better medical staff across the region are boost the growth of nasal mucosal drug delivery devices in region.
NASAL MUCOSA DRUG SUPPLY DEVICE MARKET, BY REGION, 2022 & 2032
The Nasal Mucosa Drug Supply Device Market is distinguished by the presence of numerous global, regional, and local players catering to the increasing need for products in the emerging threat. Moreover, factors such as the growing awareness of the potential for pandemics, and advances in biotechnology have made it possible to develop new and more effective nasal mucosa drug supply device products. Moreover, the numerous pipeline products are responsible for the intense competition and huge opportunities during the forecast period.
Additionally, manufacturers are entering into strategic alliances such as acquisitions, mergers, collaborations, product launches, and product approvals. These strategic alliances are creating intense rivalry for the newcomer as well as for the existing brand.
GlaxoSmithKline PLC is a science-led global healthcare company. The company’s priority is to develop and improve the pipeline of medicine. It has three major business segments, namely, pharmaceutical medicine, vaccines, and consumer healthcare products. In the year 2018, It delivers 2.3 billion packs of medicine, 770 million vaccines, and 3.8 billion consumer healthcare products. The company has a global foothold with 13 manufacturing units across ten countries, but the US market contributes major revenue. The main focus area of the company’s R&D is infectious diseases that affect the children as well as the young population in developing countries.
Key Companies in the Nasal Mucosa Drug Supply Device Market Include.
Nasal Mucosa Drug Supply Device Industry Developments
October 2021: Oyster Point Pharma’s dry-eye treatment, Tyrvaya (varenicline), received US FDA approval for its product “TYRVAYA” (varenicline solution) nasal spray for the treatment of the signs and symptoms of dry eye disease.
May 2022: Medtronic plc, a US-based medical device firm, acquired Intersect ENT Inc. for an undisclosed sum. The acquisition was adding novel products used in sinus operations to improve post-operative outcomes as well as treat nasal polyps to Medtronic’s entire ear, nose, and throat (ENT) portfolio.
| Report Attribute/Metric | Details |
| Â Market Size 2022 | USD 77.71 billion |
| Â Market Size 2023 | USD 84.09 billion |
| Market Size 2032 | USD 178.47 billion |
| Compound Annual Growth Rate (CAGR) | 7.4% (2023- 2032) |
| Base Year | 2022 |
| Forecast Period | 2023- 2032 |
| Historical Data | 2019 & 2020,2021 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Disease Type, Treatment, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | GSK plc (UK), AstraZeneca (UK), Pfizer, Inc (US) Becton, Dickinson, and Company (US), Dr. Reddy's Laboratories (India), Cadila Pharmaceuticals Ltd (India), B.F. Ascher & Company, Inc (US), Douglas Pharmaceuticals Ltd (New Zealand), ENT Technologies Pty. Ltd (Australia), NAVEH Pharma Ltd (Israel) and others |
| Key Market Opportunities | ·      Increasing technologic innovation and new product development |
| Key Market Dynamics | ·      Increasing prevalence of respiratory disease across the globe |
Nasal Mucosa Drug Supply Device Market Highlights:
Frequently Asked Questions (FAQ) :
The Nasal Mucosa Drug Supply Device Market is anticipated to reach USD 84.09 billion by at a CAGR of 7.4% during the forecast period of 2023 to 2032.
The US nasal mucosa drug supply device market is anticipated to reach USD 11.78 billion in 2023 at a CAGR of 7.6% during the forecast period of 2023 to 2032.
The Nasal Mucosa Drug Supply Device Market is expected to register a CAGR of 7.4% during the forecast period of 2023 to 2032.
The North America nasal mucosa drug supply device market accounted for USD 19.45 billion in 2023 and is expected to exhibit a 6.7% CAGR during the study period.
GSK plc (UK), AstraZeneca (UK), Pfizer, Inc (US), Becton, Dickinson, and Company (US), Dr. Reddy's Laboratories (India), Cadila Pharmaceuticals Ltd (India), B.F. Ascher & Company, Inc (US), Douglas Pharmaceuticals Ltd (New Zealand), ENT Technologies Pty. Ltd (Australia), NAVEH Pharma Ltd (Israel and others
The dry powder inhaler segment held the majority share in 2022 contributing to around 65.0% with respect to the Nasal Mucosa Drug Supply Device Market.
The asthma segment held the majority share in 2022 contributing to around 89.5% with respect to the Nasal Mucosa Drug Supply Device Market.
The retail pharmacies segment held the majority share in 2022 contributing to around 56.8% with respect to the Nasal Mucosa Drug Supply Device Market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
